Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-03-08
2009-12-22
Lewis, Patrick T (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S035000, C514S025000, C514S023000, C536S004100, C536S013200, C536S013800
Reexamination Certificate
active
07635685
ABSTRACT:
A novel group of aminoglycosides which share some structural features of currently available aminoglycosides with regard to the backbone, while also having significant structural differences, is disclosed. The similarity enables these aminoglycosides to be highly potent and effective antibiotics, while the significant differences enable these aminoglycosides to reduce or even block antibiotic resistance. The aminoglycosides of the present invention are suitable for inhibition of antrax lethal factor, hence are suitable for use as a cure for anthrax.
REFERENCES:
patent: 5096596 (1992-03-01), Hellenbrand et al.
patent: 5470836 (1995-11-01), Donno et al.
patent: 6541456 (2003-04-01), Swayze et al.
patent: 2005/0004052 (2005-06-01), Baasov et al.
patent: WO 2005/002497 (2005-01-01), None
Duynstee et al. (Tetrahedron (1999), 55(32), 9881-9898) (Abstract Sent).
Fridman et al “A New Class Of Branched Aminoglycosides: Pseudo-Pentasaccharide Derivates Of Neomycin B”Organic Letters, 5(20), 3575-3578 Coden: Orlef7; ISSN: 1523-7060, 2003, XPoo2383292 abstract; figure 1; table I.
Lee, Lac V. et al “Inhibition Of The Proteolytic Activity of Anthrax Lethal Factor By Aminoglycosides”, Journal of the american Chemical society, 126(15), 4774-4775 Coden: Jacsat; ISSN: 0002-7863, Mar. 27, 2004—XP002383293.
Bryskier, A. “Bacillus Anthracis and Antibacterial Agents”, Clinical Microbiology and Infection, 8(8), 467-478 Coden: CM1NFM;—ISSN: 1198-734X, 2002, XP002383294 p. 468, right-hand column, last line p. 469, right-hand column, line 3.
Fridman, Micha et al. “Dual Effect of Synthetic Aminoglycosides: Antibacterial Activity Against Bacillus Anthracis and Inhibition of Anthrax Lethal Factor”, Angewandte Chemie, Iternaitonal Edition, 44(3), 447-452 Coden: ACIEF5; ISSN:1433-7851, 2005, XP002383295.
Hainrichson et al. “Branched Aminoglycosides: Biochemical Studies and Antibacterial Activity of Neomycin B Derivatives”, Bioorganic & Medicinal Chemistry, Elsevier Science Ltd. GB, vol. 13, No. 20,—Oct. 15, 2005, pp. 5797-5807, XP005016768, ISSN: 0986-0896 p. 5798, right-hand column, paragraph 1-6; figure 1.
IPRP CH 1 of 22 Mar. 2007.
IPRP Ch I of 26 May 2006.
SR+WO dated Jun. 19, 2006.
Kotra et al. “Aminoglycosides: Perspectives on Mechanisms of Action and Resistance and Strategies to Counter Resistance”, Antimicrobial Agents and Chemotherapy, 44(12): 3249-3256, 2000.
Fong et al. “Substrate Promiscuity of An Aminoglycoside Antibiotic Resistance Enzyme Via Target Mimicry”, The EMBO Journal, 21(10): 2323-2331, 2002.
Alper et al. “Probing the Specificity of Aminoglycoside—Ribosomal RNA Interactions With Designed Synthetic Analogs”, Journal of American Chemical Society, 120: 1965-1978, 1998.
Greenberg et al. “Design and Synthesis of New Aminoglycoside Antibiotics Containing Neamine as An Optimal Core Structure: Correlation of Antibiotic Activity With In Vitro Inhibition of Translation”, Journal of American Chemical Society, 121: 6527-6541, 1999.
Wang et al. “The Synthesis of L-Aminosugar and the Studies of L-Pyranoses on the Ring III of Pyranmycins”, Organic Letters, 4(23): 3997-4000, 2002.
Hanessian et al. “Tobramycin Analogues With C-5 Aminoalkyl Ether Chains Intended to Minimize Rings III and IV of Paromomycin”, Tetrahedron, 59: 983-993, 2003.
Haddad et al. “Design of Novel Antibiotics That Bind to the Ribosomal Acyltransfer Site”, Journal of American Chemical Society, 124: 3229-3237, 2002.
Mingeot-Leclercq et al. “Aminoglycosides: Activity and Resistance”, Antimicrobial Agents and Chemotherapy, 43(4): 727-737, 1999.
Baasov Timor
Belakhov Valery
Fridman Micha
Yaron Sima
Henry Michael C
Lewis Patrick T
Technion Research & Development Foundation Ltd.
LandOfFree
Bifunctional antibiotics for targeting rRNA and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bifunctional antibiotics for targeting rRNA and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bifunctional antibiotics for targeting rRNA and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4109466